As of 1:30 PM on the 28th, Celltrion is trading at 240,000 KRW, up 0.42% from the previous day. The trading volume is 242,759 shares, which is about 38.3% of the previous day's volume. Celltrion is known as a protein and biopharmaceutical manufacturing company.
On October 27, researcher Lee Dal-mi from SK Securities stated, "The company’s COVID-19 treatment drug is currently in phases 2 and 3 of clinical trials. They aim to announce phase 2 results by the end of 2020, and if the results are favorable, they plan to apply for emergency use authorization. The drug could be launched as early as the beginning of 2021. Although there may be some burden regarding clinical trial costs, it is expected not to exceed the usual annual clinical cost level (30% of sales), so it should not be a significant burden. At this point, it is considered an opportunity for low-price buying." Lee set Celltrion’s target price at 370,000 KRW.
Over the past five days, individual investors have net purchased 105,288 shares of Celltrion, while foreign investors and institutions have net purchased 110,891 shares and net sold 215,787 shares, respectively.
※ Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
